Schwartz Center Receives $500,000 Grant from the Amgen Foundation
- Details
- Category: Amgen
The Schwartz Center for Compassionate Healthcare, a Boston-based nonprofit dedicated to strengthening the relationship between patients and their healthcare providers, today announced it has received a $500,000 grant from the Amgen Foundation.
Roche Annual General Meeting 2012
- Details
- Category: Roche
Roche's Annual General Meeting, held today in Basel, approved all of the Board of Directors' proposals. The 755 shareholders in attendance, representing 87.4% of a total of 160,000,000 bearer shares, approved Roche's 2011 Annual Report and Financial Statements.
GSK announces submissions for two influenza vaccines
- Details
- Category: GlaxoSmithKline
GSK has submitted US and EU regulatory applications seeking approval of a quadrivalent influenza vaccine for the "active immunisation of adults and children from 3 years of age for the prevention of influenza disease caused by influenza virus types A and B contained in the vaccine."
Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE:LLY) announced the launch of its global Innovation Starts Here initiative which supports Lilly's commitment to speeding the delivery of innovative new medicines to patients around the world.
GSK and Daiichi Sankyo vaccines joint venture to become largest vaccines company in Japan
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced that it has signed an agreement with Daiichi Sankyo Co., Ltd. to form a Joint Venture (JV) which is expected to create the number one vaccines company in Japan.
FDA approves first four-strain flu vaccine
- Details
- Category: AstraZeneca
AstraZeneca announced that MedImmune, its biologics arm, has received approval from the US Food and Drug Administration (FDA) for FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) in the prevention of influenza. This marks the first four-strain influenza vaccine approved by the FDA.
Bristol-Myers Squibb and Duke Translational Medicine Institute form strategic relationship
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Duke Translational Medicine Institute (DTMI) announced the formation of a strategic relationship to broaden interactions between the two organizations. The relationship builds on a decade of collaboration in cardiology, endocrinology, and oncology,
More Pharma News ...
- Sanofi and Astellas to dissolve sanofi-aventis Yamanouchi Pharmaceutical Inc.
- Pfizer acquires Alacer Corp., a leading vitamin supplements company
- Sanofi and the Institut Pasteur create four prestigious awards
- Merck announces efficiency program across all businesses and regions
- Boehringer Ingelheim and Xencor enter a collaboration agreement
- BRILINTA® added to American College of Chest Physicians recommendations
- Pfizer and Hisun announce progress on potential joint venture